| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Ciwujianoside C3 does not have a single well-defined pharmacological target; it exhibits pleiotropic effects through modulation of multiple cellular pathways. It has anti-inflammatory effects and can reinforce object recognition memory. As a triterpenoid saponin, it may interact with cell membranes and modulate signaling pathways involved in inflammation and cognition. Its ability to penetrate the blood-brain barrier makes it valuable for studying central nervous system effects.
|
|---|---|
| ln Vitro |
In vitro, ciwujianoside C3 has anti-inflammatory effects. It is a triterpenoid saponin that modulates inflammatory responses in various cell types. Its ability to cross the blood-brain barrier suggests potential effects on neuronal cells. However, specific in vitro data, including IC50 values and detailed cellular mechanisms, are not extensively reported in the available literature. Further studies are needed to fully characterize its cellular activity.
|
| ln Vivo |
In vivo, ciwujianoside C3 is orally active and brain-penetrant. It has anti-inflammatory effects and enhances object recognition memory in individual mice. These properties make it a potential candidate for studying cognitive enhancement and neuroinflammation. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile.
|
| Enzyme Assay |
Cell-free assays for ciwujianoside C3 involve characterizing its chemical properties and purity. Its identity is confirmed by HPLC, NMR, and mass spectrometry. As a saponin, its physicochemical properties such as solubility and stability can be measured. The compound is typically stored desiccated at -20°C. Detailed cell-free biological assay protocols are not extensively reported in the available literature.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: RAW 264.7 Cell Tested Concentrations: 10 µM, 20 µM and 40 µM Incubation Duration: 24 hrs (hours) Experimental Results: No effect on cytotoxicity and inhibition of NO production Western Blot Analysis[1] Cell Types: RAW 264.7 Cells Tested Concentrations: 10 µM, 20 µM and 40 µM Incubation Duration: 24 hrs (hours) Experimental Results: diminished p-ERK and p-JNK expression. RT-PCR[1] Cell Types: RAW 264.7 Cell Tested Concentrations: 10 µM, 20 µM and 40 µM Incubation Duration: 24 hrs (hours) Experimental Results: COX-2 and iNOS mRNA expression diminished in a dose-dependent manner. In vitro cellular assays for ciwujianoside C3 would typically involve treating immune cells or neuronal cells with various concentrations of the compound. Anti-inflammatory activity would be assessed by measuring cytokine production in activated macrophages. Effects on cognition would be studied in neuronal cell models. However, specific assay protocols are not extensively documented in the available literature. The compound is typically dissolved in DMSO and diluted in cell culture medium for in vitro studies. |
| Animal Protocol |
Animal/Disease Models: Mice [1]
Doses: 0.5 mg/kg Route of Administration: po (po (oral gavage)) 0.5 mg/kg/day; 17 days Experimental Results: Strengthened object recognition memory. In vivo animal studies for ciwujianoside C3 are conducted in mouse models. The compound is administered orally. Object recognition memory is assessed using behavioral tests such as the novel object recognition test. Anti-inflammatory effects are evaluated by measuring inflammatory markers in tissues. Brain penetration is confirmed by measuring drug concentrations in brain tissue. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ciwujianoside C3 include a molecular weight of 1059.25 g/mol and molecular formula C53H86O21. It is orally active and can penetrate the blood-brain barrier. The compound is typically stored desiccated at -20°C. As a triterpenoid saponin, it is expected to have moderate oral bioavailability. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ciwujianoside C3 has not been extensively characterized in published literature. As a natural product from Acanthopanax senticosus, it is generally considered to have a favorable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans. Standard safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
According to reports, ciuganoside C3 has been found in hibiscus, clematis, and other organisms with available data.
Ciwujianoside C3 is an orally active, brain-penetrant triterpenoid saponin from Acanthopanax senticosus with anti-inflammatory effects and the ability to enhance object recognition memory. Its molecular formula is C53H86O21 with a molecular weight of 1059.25 g/mol. Ciwujianoside C3 is a research tool for studying inflammation and cognition. It has not entered clinical trials and is strictly for research purposes. |
| Molecular Formula |
C53H86O21
|
|---|---|
| Molecular Weight |
1059.2374
|
| Exact Mass |
1058.566
|
| CAS # |
114906-74-0
|
| PubChem CID |
21626481
|
| Appearance |
White to off-white solid powder
|
| Density |
1.43±0.1 g/cm3(Predicted)
|
| Source |
Originated from plants: Araliaceae Acanthopanax henryi (Oliv.) Harms
|
| LogP |
0.4
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
74
|
| Complexity |
2040
|
| Defined Atom Stereocenter Count |
27
|
| SMILES |
C(O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)[C@H]2O)O1)O)O)O)(=O)[C@@]12CC[C@]3(C)C(=CC[C@H]4[C@@]3(C)CC[C@@H]3[C@]4(C)CC[C@@H](C3(C)C)O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)CO3)[C@@H]1CC(C)(C)CC2
|
| InChi Key |
XPZZGRWYXQODIS-SEHMIGTGSA-N
|
| InChi Code |
InChI=1S/C53H86O21/c1-23-32(56)35(59)39(63)45(69-23)73-42-27(20-54)70-43(41(65)37(42)61)68-22-28-34(58)36(60)40(64)46(71-28)74-47(66)53-17-15-48(2,3)19-25(53)24-9-10-30-50(6)13-12-31(72-44-38(62)33(57)26(55)21-67-44)49(4,5)29(50)11-14-52(30,8)51(24,7)16-18-53/h9,23,25-46,54-65H,10-22H2,1-8H3/t23-,25-,26-,27+,28+,29-,30+,31-,32-,33-,34+,35+,36-,37+,38+,39+,40+,41+,42+,43+,44-,45-,46-,50-,51+,52+,53-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~47.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (1.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (1.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9441 mL | 4.7204 mL | 9.4407 mL | |
| 5 mM | 0.1888 mL | 0.9441 mL | 1.8881 mL | |
| 10 mM | 0.0944 mL | 0.4720 mL | 0.9441 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
